JP2023511277A5 - - Google Patents
Info
- Publication number
- JP2023511277A5 JP2023511277A5 JP2022542918A JP2022542918A JP2023511277A5 JP 2023511277 A5 JP2023511277 A5 JP 2023511277A5 JP 2022542918 A JP2022542918 A JP 2022542918A JP 2022542918 A JP2022542918 A JP 2022542918A JP 2023511277 A5 JP2023511277 A5 JP 2023511277A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ccr5
- tumor
- seq
- metastatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960613P | 2020-01-13 | 2020-01-13 | |
| US62/960,613 | 2020-01-13 | ||
| US202062968954P | 2020-01-31 | 2020-01-31 | |
| US62/968,954 | 2020-01-31 | ||
| US202062977023P | 2020-02-14 | 2020-02-14 | |
| US62/977,023 | 2020-02-14 | ||
| PCT/US2021/013289 WO2021146323A1 (en) | 2020-01-13 | 2021-01-13 | Ccr5 binding agent for treatment of ccr5 positive metastatic breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023511277A JP2023511277A (ja) | 2023-03-17 |
| JP2023511277A5 true JP2023511277A5 (https=) | 2024-03-18 |
Family
ID=76760851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542918A Pending JP2023511277A (ja) | 2020-01-13 | 2021-01-13 | Ｃｃｒ５陽性の転移性のがんの処置のためのｃｃｒ５結合剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210214448A1 (https=) |
| EP (1) | EP4090675A4 (https=) |
| JP (1) | JP2023511277A (https=) |
| KR (1) | KR20220127859A (https=) |
| CN (1) | CN115003691A (https=) |
| AU (1) | AU2021207851A1 (https=) |
| BR (1) | BR112022012821A2 (https=) |
| CA (1) | CA3163060A1 (https=) |
| IL (1) | IL294113A (https=) |
| MX (1) | MX2022008632A (https=) |
| WO (1) | WO2021146323A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021019405A2 (pt) * | 2019-04-01 | 2021-11-30 | Cytodyn Inc | Agentes anti-ccr5 e métodos de tratamento que bloqueiam a metástase do câncer ou aumentam a morte celular induzida pela quimioterapia prejudicial ao dna |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122185B2 (en) * | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
| NZ534947A (en) * | 2002-02-22 | 2008-03-28 | Progenics Pharm Inc | Anti-CCR5 antibody that binds to CCR5 on the surface of a human cell. |
| WO2007113648A2 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| JP6518585B2 (ja) * | 2012-05-14 | 2019-05-22 | リチャード ジー． ペステル | がんの治療のためのｃｃｒ５の修飾薬の使用 |
| CN106413751A (zh) * | 2014-05-21 | 2017-02-15 | 辉瑞大药厂 | 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合 |
| WO2016073380A1 (en) * | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment |
| CN107847514A (zh) * | 2015-06-23 | 2018-03-27 | 西托戴恩股份有限公司 | 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变 |
| KR20190003958A (ko) * | 2016-04-15 | 2019-01-10 | 제넨테크, 인크. | 암의 치료 및 모니터링 방법 |
| WO2018085513A1 (en) * | 2016-11-04 | 2018-05-11 | Genentech, Inc. | Treatment of her2-positive breast cancer |
| CN111886249A (zh) * | 2017-09-18 | 2020-11-03 | 西托戴恩股份有限公司 | 用于鉴定和治疗适合长期抗-ccr5剂治疗的hiv-1感染患者亚群的筛选方法 |
| EP3773676A4 (en) * | 2018-04-03 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams |
| CN112639137A (zh) * | 2018-07-02 | 2021-04-09 | 茵赛德斯有限公司 | 用于检测癌症相关细胞群体、进行转移性癌症筛查及治疗的方法 |
| BR112021019405A2 (pt) * | 2019-04-01 | 2021-11-30 | Cytodyn Inc | Agentes anti-ccr5 e métodos de tratamento que bloqueiam a metástase do câncer ou aumentam a morte celular induzida pela quimioterapia prejudicial ao dna |
-
2021
- 2021-01-13 AU AU2021207851A patent/AU2021207851A1/en active Pending
- 2021-01-13 KR KR1020227027622A patent/KR20220127859A/ko active Pending
- 2021-01-13 MX MX2022008632A patent/MX2022008632A/es unknown
- 2021-01-13 IL IL294113A patent/IL294113A/en unknown
- 2021-01-13 EP EP21741191.7A patent/EP4090675A4/en not_active Withdrawn
- 2021-01-13 BR BR112022012821A patent/BR112022012821A2/pt unknown
- 2021-01-13 US US17/148,281 patent/US20210214448A1/en not_active Abandoned
- 2021-01-13 CA CA3163060A patent/CA3163060A1/en active Pending
- 2021-01-13 WO PCT/US2021/013289 patent/WO2021146323A1/en not_active Ceased
- 2021-01-13 CN CN202180008905.1A patent/CN115003691A/zh active Pending
- 2021-01-13 JP JP2022542918A patent/JP2023511277A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024037894A5 (https=) | ||
| JP2020528750A5 (https=) | ||
| JP2023113893A5 (https=) | ||
| HRP20171758T1 (hr) | Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene | |
| JP2019519499A5 (https=) | ||
| RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| FI3802608T3 (fi) | Cd3-vasta-aineita ja niiden käyttötapoja | |
| RU2014108049A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| JP2022511394A5 (https=) | ||
| JP2020521778A5 (https=) | ||
| RU2012137505A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2010142390A (ru) | Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения | |
| JP2022512750A5 (https=) | ||
| RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| JP2020522281A5 (https=) | ||
| WO2017091429A1 (en) | Combination therapy for cancer | |
| JP2024545428A5 (https=) | ||
| JP2023539589A5 (https=) | ||
| JP2023511277A5 (https=) | ||
| JPWO2022270524A5 (https=) | ||
| Bhaskara et al. | Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases | |
| JP2020535180A5 (https=) | ||
| JP2022542524A5 (https=) | ||
| JP2023517671A5 (https=) | ||
| JP2023503031A5 (https=) |